Search

Your search keyword '"Flatmark, Kjersti"' showing total 600 results
Start Over Author "Flatmark, Kjersti"
600 results on '"Flatmark, Kjersti"'

5. ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series

Author

Ambrosini, Margherita, Del Re, Marzia, Manca, Paolo, Hendifar, Andrew, Drilon, Alexander, Harada, Guilherme, Ree, Anne Hansen, Klempner, Samuel, Mælandsmo, Gunhild Mari, Flatmark, Kjersti, Russnes, Hege G, Cleary, James M, Singh, Harshabad, Sottotetti, Elisa, Martinetti, Antonia, Randon, Giovanni, Sartore-Bianchi, Andrea, Capone, Iolanda, Milione, Massimo, Di Bartolomeo, Maria, and Pietrantonio, Filippo

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Rare Diseases, Cancer, Aetiology, 2.1 Biological and endogenous factors, Carcinoma, Non-Small-Cell Lung, Crizotinib, Gastrointestinal Neoplasms, Humans, Lung Neoplasms, Prospective Studies, Protein Kinase Inhibitors, Oncology and carcinogenesis
Abstract

PurposeIn GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non-small-cell lung cancer but may be important to offer personalized strategies of treatment in selected patients. Data about the activity and efficacy of ALK inhibitors (ALKi) in GI cancers are scarce.Materials and methodsWe assembled a clinical and molecular international data set of pretreated patients with metastatic or nonresectable cancers of GI primary tumor origin with documented ALK rearrangement treated with at least one line of ALKi. Measurable disease as per RECIST 1.1 was required for response analysis.ResultsPrimary tumor sites were distributed as follows: 5 (38%) pancreas, 3 (23%) right colon, and 1 (8%) for each one of gastric, duodenal, rectal, left colon, and biliary tract sites. Seven patients (54%) were treated with alectinib, 5 (38%) with crizotinib, and 1 (8%) with entrectinib. After disease progression, five patients (38%) received a subsequent ALKi treatment line, and at the time of data cutoff date, treatment was still ongoing in two patients. Five of 12 evaluable patients (41%) achieved a partial response to first-line ALKi, five patients (41%) had stable disease, and 2 (17%) had progressive disease. No complete responses were registered. At a median follow-up of 39.6 months (interquartile range: 19.8-59.5), the median progression-free survival was 5.0 months (95% CI, 3.68 to no response) and the median overall survival was 9.3 months (95% CI, 5.46 to no response).ConclusionTreatment with ALKi provides remarkable responses and clinical benefit in pretreated patients with ALK fusion-positive GI malignancies. Despite the rarity, ALK rearrangements represent an important therapeutic target in individual pretreated patients with GI solid tumors. Further work providing prospective clinical validation of this target is needed.

Published
2022

8. Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei

Author

Patrick-Brown Thale D.J.H., Mohamed Faheez, Thrower Andrew, Torgunrud Annette, Cosyns Sarah, Canbay Emel, Villeneuve Laurent, Flatmark Kjersti, and Brandl Andreas

Subjects
biobanking, data science, investigative techniques, neoplasm, peritoneum, pseudomyxoma peritonei, Medicine, Specialties of internal medicine, RC581-951
Abstract

Pseudomyxoma peritonei (PMP) is a rare cancer currently affecting over 11,736 patients across Europe. Since PMP is so uncommon, collaboration between scientific centers is key to discovering the mechanisms behind the disease, efficient treatments, and targets pointing to a cure. To date, no consensus has been reached on the minimum data that should be collected during PMP research studies. This issue has become more important as biobanking becomes the norm. This paper begins the discussion around a minimum data set that should be collected by researchers through a review of available clinical trial reports in order to facilitate collaborative efforts within the PMP research community.

Published
2023
Full Text
View/download PDF

11. Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.

Author

Ree, Anne Hansen, Høye, Eirik, Esbensen, Ying, Beitnes, Ann-Christin R., Negård, Anne, Bernklev, Linn, Tetlie, Linn Kruse, Fretland, Åsmund A., Hamre, Hanne M., Kersten, Christian, Hofsli, Eva, Guren, Marianne G., Sorbye, Halfdan, Nilsen, Hilde L., Flatmark, Kjersti, and Meltzer, Sebastian

Abstract

The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB). Three of 38 patients assigned to this experimental treatment had metastases from BRAF-mutant MSS-CRC, in general a poor-prognostic subgroup explored here. The ≥70-year-old females presented with ascending colon adenocarcinomas with intermediate tumor mutational burden (6.2–11.8 mutations per megabase). All experienced early disappearance of the primary tumor followed by complete response of all overt metastatic disease, resulting in progression-free survival as long as 20–35 months. However, they encountered recurrence at previously unaffected sites and ultimately sanctuary organs, or as intrahepatic tumor evolution reflected in the terminal loss of initially induced T-cell clonality in liver metastases. Yet, the remarkable first-line responses to short-course oxaliplatin-based chemotherapy alternating with ICB may offer a novel therapeutic option to a particularly hard-to-treat MSS-CRC subgroup. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients With Peritoneal and Liver Metastases From Colorectal Cancer.

Author

Dagenborg, Vegar Johansen, Brudvik, Kristoffer Watten, Lund-Andersen, Christin, Torgunrud, Annette, Lund-Iversen, Marius, Flatmark, Kjersti, Larsen, Stein Gunnar, and Yaqub, Sheraz

Abstract

Objective: To study outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in patients also treated for colorectal liver metastases (CLM). Background: Colorectal cancer (CRC) frequently metastasizes to the liver and peritoneum and is associated with a poor prognosis. In selected patients, a benefit in overall survival (OS) was shown for both peritoneal metastases (PM-CRC) offered CRS-HIPEC, and CLM treated with surgical resection. However, the presence of CLM was considered a relative contraindication to CRS-HIPEC, causing a paucity of outcome data in this patient group. Methods: Patients with PM-CRC having CRS-HIPEC at a single national center between 2007 and 2023, with additional intervention for CLM, were included (previous curative treatment for extraperitoneal and extrahepatic metastases was allowed). Three groups were defined: CLM before CRS-HIPEC (pre-CRS-HIPEC), CLM resected simultaneously with CRS-HIPEC (sim-CRS-HIPEC), and CLM after CRS-HIPEC (post-CRS-HIPEC), aiming to retrospectively analyze outcomes. Results: Fifty-seven patients were included and classified as: pre-CRS-HIPEC (n = 11), sim-CRS-HIPEC (n = 29), and post-CRS-HIPEC (n = 17). Median Peritoneal Cancer Index (PCI) was 8; 13 patients had severe complications (Clavien-Dindo ≥ 3), and no 90-day mortality. Median OS was 48 months after CRS-HIPEC. PCI was a predictor of OS (hazard ratio: 1.11, P < 0.001). We observed no difference in short or long-term outcomes between intervention groups. Discussion: This study demonstrated that patients with CLM having CRS-HIPEC had comparable OS to reports on CRS-HIPEC only, likely explained by a low PCI. Simultaneous CLM resection did not increase the risk of severe complications. Conclusions: In this national cohort, CRS-HIPEC and CLM intervention offers long-term survival, suggesting that this treatment may be offered to selected patients with PM-CRC and CLM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?

Author

Meltzer, Sebastian, Bakke, Kine Mari, Rød, Karina Lund, Negård, Anne, Flatmark, Kjersti, Solbakken, Arne Mide, Kristensen, Annette Torgunrud, Fuglestad, Anniken Jørlo, Kersten, Christian, Dueland, Svein, Seierstad, Therese, Hole, Knut Håkon, Lyckander, Lars Gustav, Larsen, Finn Ole, Schou, Jakob Vasehus, Patrick Brown, Dawn, Abrahamsson, Hanna, Redalen, Kathrine Røe, and Ree, Anne Hansen

Published
2020
Full Text
View/download PDF

17. Enrichment of circulating helper-T (Th) and unswitched memory-B (NSwM-B) cell populations and responsiveness to immune checkpoint blockade (ICB) in microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) colorectal cancer (CRC).

Author

Meltzer, Sebastian, primary, Franco Ulloa, Sebastian, additional, Bjørnetrø, Tonje, additional, Hamre, Hanne M, additional, Kaveh, Fatemeh, additional, Wälchli, Sébastien, additional, Flatmark, Kjersti, additional, Inderberg, Else Marit, additional, and Ree, Anne Hansen, additional

Published
2024
Full Text
View/download PDF

23. A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases

Author

Flørenes, Vivi Ann, Flem-Karlsen, Karine, McFadden, Erin, Bergheim, Inger Riise, Nygaard, Vigdis, Nygård, Vegard, Farstad, Inger Nina, Øy, Geir Frode, Emilsen, Elisabeth, Giller-Fleten, Karianne, Ree, Anne Hansen, Flatmark, Kjersti, Gullestad, Hans Petter, Hermann, Robert, Ryder, Truls, Wernhoff, Patrik, and Mælandsmo, Gunhild Mari

Published
2019
Full Text
View/download PDF

27. Data from Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma

Author

Ito, Ichiaki, primary, Yousef, Abdelrahman M.G., primary, Chowdhury, Saikat, primary, Dickson, Princess N., primary, Naini, Zahra A., primary, White, Michael G., primary, Fleten, Karianne G., primary, Flatmark, Kjersti, primary, Fournier, Keith F., primary, Fowlkes, Natalie W., primary, and Shen, John Paul, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figures from Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma

Author

Ito, Ichiaki, primary, Yousef, Abdelrahman M.G., primary, Chowdhury, Saikat, primary, Dickson, Princess N., primary, Naini, Zahra A., primary, White, Michael G., primary, Fleten, Karianne G., primary, Flatmark, Kjersti, primary, Fournier, Keith F., primary, Fowlkes, Natalie W., primary, and Shen, John Paul, primary

Published
2023
Full Text
View/download PDF

31. Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma

Author

Ito, Ichiaki, primary, Yousef, Abdelrahman M.G., additional, Chowdhury, Saikat, additional, Dickson, Princess N., additional, Naini, Zahra A., additional, White, Michael G., additional, Fleten, Karianne G., additional, Flatmark, Kjersti, additional, Fournier, Keith F., additional, Fowlkes, Natalie W., additional, and Shen, John Paul, additional

Published
2023
Full Text
View/download PDF

32. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate

Author

Ree, Anne Hansen, Russnes, Hege G., Heinrich, Daniel, Dueland, Svein, Boye, Kjetil, Nygaard, Vigdis, Silwal-Pandit, Laxmi, Østrup, Olga, Hovig, Eivind, Nygaard, Vegard, Rødland, Einar A., Nakken, Sigve, Øien, Janne T., Johansen, Christin, Bergheim, Inger R., Skarpeteig, Veronica, Sathermugathevan, Menaka, Sauer, Torill, Lund-Iversen, Marius, Beiske, Klaus, Nasser, Salah, Julsrud, Lars, Reisse, Claudius H., Ruud, Espen A., Flørenes, ViviAnn, Hagene, Kirsten T., Aas, Eline, Lurås, Hilde, Johnsen-Soriano, Siv, Geitvik, Gry A., Lingjærde, Ole Christian, Børresen-Dale, Anne-Lise, Mælandsmo, Gunhild M., and Flatmark, Kjersti

Published
2017
Full Text
View/download PDF

36. Supplementary Table S1 from Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain

Author

Ree, Anne Hansen, primary, Nygaard, Vigdis, primary, Russnes, Hege G., primary, Heinrich, Daniel, primary, Nygaard, Vegard, primary, Johansen, Christin, primary, Bergheim, Inger Riise, primary, Hovig, Eivind, primary, Beiske, Klaus, primary, Negård, Anne, primary, Børresen-Dale, Anne-Lise, primary, Flatmark, Kjersti, primary, and Mælandsmo, Gunhild M., primary

Published
2023
Full Text
View/download PDF

37. Data from A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

Author

Nygaard, Vigdis, primary, Ree, Anne Hansen, primary, Dagenborg, Vegar Johansen, primary, Børresen-Dale, Anne-Lise, primary, Edwin, Bjørn, primary, Fretland, Åsmund Avdem, primary, Grzyb, Krzysztof, primary, Haugen, Mads H., primary, Mælandsmo, Gunhild M., primary, and Flatmark, Kjersti, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figures S1-3 from A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

Author

Nygaard, Vigdis, primary, Ree, Anne Hansen, primary, Dagenborg, Vegar Johansen, primary, Børresen-Dale, Anne-Lise, primary, Edwin, Bjørn, primary, Fretland, Åsmund Avdem, primary, Grzyb, Krzysztof, primary, Haugen, Mads H., primary, Mælandsmo, Gunhild M., primary, and Flatmark, Kjersti, primary

Published
2023
Full Text
View/download PDF

39. Data from Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain

Author

Ree, Anne Hansen, primary, Nygaard, Vigdis, primary, Russnes, Hege G., primary, Heinrich, Daniel, primary, Nygaard, Vegard, primary, Johansen, Christin, primary, Bergheim, Inger Riise, primary, Hovig, Eivind, primary, Beiske, Klaus, primary, Negård, Anne, primary, Børresen-Dale, Anne-Lise, primary, Flatmark, Kjersti, primary, and Mælandsmo, Gunhild M., primary

Published
2023
Full Text
View/download PDF

40. Supplementary File S1 from A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

Author

Nygaard, Vigdis, primary, Ree, Anne Hansen, primary, Dagenborg, Vegar Johansen, primary, Børresen-Dale, Anne-Lise, primary, Edwin, Bjørn, primary, Fretland, Åsmund Avdem, primary, Grzyb, Krzysztof, primary, Haugen, Mads H., primary, Mælandsmo, Gunhild M., primary, and Flatmark, Kjersti, primary

Published
2023
Full Text
View/download PDF

41. Abstract 3279: Systemic immune response invoked by short-course oxaliplatin-based chemotherapy (FLOX) for efficacy of sequential immune checkpoint blockade (ICB; nivolumab) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)

Author

Meltzer, Sebastian, primary, Flatmark, Kjersti, additional, Fuglestad, Anniken J., additional, Hamre, Hanne M., additional, Kersten, Christian, additional, Hofsli, Eva, additional, Guren, Marianne G., additional, Sorbye, Halfdan, additional, Negård, Anne, additional, and Ree, Anne Hansen, additional

Published
2023
Full Text
View/download PDF

42. Supplementary Data incl Figure S1 and Table S3 from Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain

Author

Ree, Anne Hansen, primary, Nygaard, Vigdis, primary, Russnes, Hege G., primary, Heinrich, Daniel, primary, Nygaard, Vegard, primary, Johansen, Christin, primary, Bergheim, Inger Riise, primary, Hovig, Eivind, primary, Beiske, Klaus, primary, Negård, Anne, primary, Børresen-Dale, Anne-Lise, primary, Flatmark, Kjersti, primary, and Mælandsmo, Gunhild M., primary

Published
2023
Full Text
View/download PDF

48. A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

Author

Nygaard, Vigdis, primary, Ree, Anne Hansen, additional, Dagenborg, Vegar Johansen, additional, Børresen-Dale, Anne-Lise, additional, Edwin, Bjørn, additional, Fretland, Åsmund Avdem, additional, Grzyb, Krzysztof, additional, Haugen, Mads H., additional, Mælandsmo, Gunhild M., additional, and Flatmark, Kjersti, additional

Published
2023
Full Text
View/download PDF

50. Stereotactical optical navigation for locally advanced and recurrent rectal cancer in the posterolateral pelvis

Author

Solbakken, Arne M., primary, Sellevold, Simen, additional, Spasojevic, Milan, additional, Julsrud, Lars, additional, Emblemsvåg, Hanne-Line, additional, Reims, Henrik, additional, Sørensen, Olaf, additional, Thorgersen, Ebbe Billmann, additional, Fauske, Lena, additional, Brennhovd, Bjørn, additional, Ryder, Truls, additional, Larsen, Stein Gunnar, additional, and Flatmark, Kjersti, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results